Skip to the page
pepts.wiki

We are not doctors and nothing here is medical advice. Always consult a medical professional first. Why we say this

Licensed medicineStub

Liraglutide

GLP-1 receptor agonist

A GLP-1 receptor agonist given once daily by injection. It is a licensed medicine for type 2 diabetes and for weight management.

Reconstitution calculator

At a glance

Licensed medicine

A regulator has licensed it for at least one use, in at least one country. That says nothing about uses outside the license.

This page is a stub

The wiki has this compound's identity from the My-Pepts library, its standing, and what PubMed holds for it. The article, with its studies read and cited, is not written yet. Until it is, the counts below say how much research exists, not what it found.

How strong is the evidence

How far it has climbed

Every medicine climbs the same ladder. Most compounds never reach the top, and where one stands says how much its claims can carry.

  1. Licensed medicine: Liraglutide

    A regulator has reviewed the trials and licensed it for a named use.

  2. Phase 3

    Large randomized trials, often thousands of people, against placebo or a standard treatment.

  3. Phase 2

    Mid-sized trials that measure dose against effect in people with the condition.

  4. Phase 1 and early human studies

    First studies in people: safety, and how the body handles it.

  5. Cells and animals

    Laboratory and animal work. An animal result is not a result in people.

2,619
papers on PubMed
1,463
of them in people
431
randomized trials
250
reviews

A count says how much has been published, not what it found. Counted on PubMed: 2026-11-16

Handling and reconstitution

From powder to a measured sample

The same four steps for any lyophilized vial. Laboratory handling, not use in a person.

  1. 1. Read the vial

    The label gives the mass of peptide in the vial, in milligrams. That number is the start of every calculation.

  2. 2. Add the diluent

    A measured volume of diluent goes in slowly, down the glass. Swirl gently; shaking can damage a peptide.

  3. 3. Work out the strength

    Concentration is mass divided by volume: 10 mg in 2 mL is 5 mg per mL.

  4. 4. Measure the sample

    Volume is the mass wanted divided by the concentration. On a U-100 syringe, 1 mL is 100 units.

The calculator below does the arithmetic and shows its working.

As powder

General practice for lyophilized peptides: keep the sealed vial frozen or refrigerated, dry and away from light, and follow the supplier's certificate of analysis.

In solution

Once in solution a peptide is kept refrigerated and used within the period the supplier states. A vial drawn from more than once needs a preserved diluent such as bacteriostatic water.

This is general practice for lyophilized peptides, not data on Liraglutide itself. The batch's certificate of analysis and the supplier's sheet are the facts to go by. More on storage

Reconstitution calculator

Opens on vial sizes common for research peptides. Change any number. How the arithmetic works

Draw to

10 units

0.1 mL on a U-100 syringe

Concentration
2.5 mg/mL
Each unit holds
25 mcg
Samples in the vial
20
Sample
250 mcg

5 mg in 2 mL is 2.5 mg/mL. 250 mcg of that is 0.1 mL, which reads as 10 units. This is arithmetic for a vial of Liraglutide; no amount here is a recommendation.

Liraglutide: on PubMed

What PubMed held for Liraglutide on November 16, 2026. A count says how much a compound has been studied, not what the studies found: how to read these numbers.

2,619
papers
1,463
in humans
476
clinical trials
431
randomized trials
2012: 86 papers122013: 94 papers2014: 126 papers142015: 186 papers2016: 200 papers162017: 186 papers2018: 187 papers182019: 254 papers2020: 225 papers202021: 214 papers2022: 191 papers222023: 203 papers2024: 215 papers242025: 245 papers2026: 184 papers so far26
Papers per year, 2012 to 2026. The most in one year: 254.

Most relevant on PubMed

Listed by PubMed's own relevance ranking, trials and reviews first. The wiki has not read these into the article unless they are also among its sources.

  1. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

    Randomized trialMarso SP, Daniels GH, Brown-Frandsen K, et al. The New England journal of medicine, 2016. PMID 27295427

  2. Liraglutide for Children 6 to <12 Years of Age with Obesity - A Randomized Trial

    Randomized trialFox CK, Barrientos-Pérez M, Bomberg EM, et al. The New England journal of medicine, 2025. PMID 39258838

  3. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial

    Randomized trialRubino DM, Greenway FL, Khalid U, et al. JAMA, 2022. PMID 35015037

  4. Comparative effectiveness of semaglutide versus liraglutide, dulaglutide or tirzepatide: a systematic review and meta-analysis

    ReviewKarimi MA, Gholami Chahkand MS, Dadkhah PA, et al. Frontiers in pharmacology, 2025. PMID 40444045

  5. Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined

    Randomized trialLundgren JR, Janus C, Jensen SBK, et al. The New England journal of medicine, 2021. PMID 33951361

  6. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management

    Randomized trialPi-Sunyer X, Astrup A, Fujioka K, et al. The New England journal of medicine, 2015. PMID 26132939

  7. Liraglutide

    StudyCerillo JL, Parmar M , 2024. PMID 39383283

  8. Liraglutide-Induced Hepatotoxicity

    StudyMaor Y, Ergaz D, Malnick SDH, et al. Biomedicines, 2021. PMID 33498980

Search used: ("Liraglutide"[ti]). Run it on PubMed

Research links

Also in Metabolic